EU Approves Takeda’s Injectable Entyvio for IBD
EU OK Follows FDA’s Recent Rejection Of The New Formulation
Executive Summary
Takeda has won EU approval for an injectable version of Entyvio to treat ulcerative colitis or Crohn’s disease, in contrast to the FDA’s rejection in December.
You may also be interested in...
Takeda Feels Confident Of No Entyvio Biosimilars Until Early 2030s
Biosimilar vedolizumab rivals to Takeda’s Entyvio blockbuster will not materialize in the current decade, the Japanese originator has forecasted as part of a significantly extended IP landscape.
Takeda Introduces Vedolizumab In India Amid Signs Of Gear Shift
Takeda launches blockbuster gastrointestinal drug vedolizumab in India, stepping up the tempo on the back of the local base provided by its acquisition of Shire. More expansion in the country appears to be in store for the Japanese firm.
Takeda Forecasts Tripling In Reported Op Profit Despite Virus Uncertainties
While it has seen no coronavirus-related business impact so far and uncertainties remain, Takeda expects lower costs related to the Shire acquisition to propel its profits this fiscal year.